3 results
The purpose of this Phase 3 study is to evaluate the safety and clinical efficacy of ligelizumab 240 mg and 120 mg given subcutaneously (s.c.) every 4 weeks (q4w) to ensure protection against allergic reaction by decreasing the sensitivity to oral…
The aim of this study is to evaluate the efficacy of three doses of S 066913 (5 mg, 25 mg and 100 mg o.d.) versus placebo administered for 4 weeks on atrial fibrillation and/or atrial tachycardia burden (AF/AT burden) in patients with paroxysmal…
The purpose of the study is to establish the efficacy and safety of ligelizumab in treating adult and adolescent subjects with chronic spontaneous urticaria. This study also looks how:• further treatment of ligelizumab works following ligelizumab or…